Aitia

Aitia is a biotechnology company focused on discovering and developing breakthrough medicines by revealing the biological mechanisms that drive human disease. Its Gemini Digital Twin platform combines proprietary causal artificial intelligence, a simulation and reverse-engineering engine, supercomputing, and large-scale human multi-omics and clinical data. The platform creates in silico models of disease biology to map molecular interactions, identify potential drug targets, and uncover biomarkers that may help predict patient responses.

Aitia says its discoveries are validated in laboratory and clinical settings and translated into drug development programs with biopharmaceutical partners. Its work supports the search for first-in-class and best-in-class precision therapies in areas of significant unmet medical need, including cancer, neurodegenerative, immunological, and cardiometabolic diseases. The company collaborates with pharmaceutical partners, combining its technology, data, and biological expertise with their research and development capabilities to advance new therapies. Based in Cambridge, Massachusetts, Aitia brings together specialists in artificial intelligence, research and development, and biotechnology company building.